CBI

Clal Biotechnology Industries – a leading Israeli life sciences investment company

about cbi

Clal Biotechnology Industries is a leading Israeli life sciences investment company traded on the Tel Aviv Stock Exchange (TASE: CBI). CBI supports life science ventures by identifying and empowering science-backed projects and proactively guiding them to fruition

portfolio

The CBI portfolio is comprised of biotechnology and medical device companies developing breakthrough solutions for serious unmet medical needs, while offering substantial value and investment potential.

+

Cactus Acquisition Corp. 1

The Cactus Acquisition Corp. 1 (Nasdaq: CCTSU) is a SPAC focusing on Isareli-related targets in the healthcare business
+

MediWound

MediWound (Nasdaq: MDWD) is a specialty biotechnology company focused on severe burn and chronic wound management.
+

Gamida Cell

Gamida Cell is a cell and immune therapy visionary. Gamida Cell's lead product, omidubicel, has recently successfully completed a phase III clinical trial in hematological malignancies.
+

Elicio

Elicio develops platform technologies to deliver agents directly to the antigen-presenting cells of the lymph nodes with many potential applications in cancer and infectious diseases.
+

Cadent Therapeutics

Cadent Therapeutics is developing innovative drugs for neurological and psychiatric disorders. This company has been recently acquired by Novartis.
+

Exithera

eXIthera Pharmaceuticals is a clinical stage biotech company discovering and developing small molecule inhibitors of Factor XIa, which offer the potential of thrombosis prevention without the bleeding liabilities.
+

Biokine

Biokine Therapeutics is developing novel therapeutics to treat cancer. It's lead product, motixafortide (formerly BL-8040), is licensed to BiolineRx and is currently in phase III clinical development.

See complete portfolio

Press Releases

2023

01

Aug

MediWound Announces Commercial Launch of NexoBrid® in Japan
10

Jul

MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
03

Jul

MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design
05

Mar

Elicio Therapeutics Anounces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Imunotherapy, ELI-02, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer athe ASCO Anual Meting Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting
30

May

MediWound Reports First Quarter 2023 Financial Results
05

Jan

Elicio Therapeutics Anounces Completion of Merger with Angion Biomedica

Read all Press Releases